Quest Magazine

Sailormen Inc. Popeyes Annual ‘Appetite For A Cure’ Campaign Helps Fight Back Against Muscular Dystrophy

PTC Therapeutics Provides Update On CHMP Opinion For Conditional Approval Of Ataluren For Nonsense Mutation Duchenne Muscular Dystrophy

MMD2: Designer Compounds Free a Trapped Protein

FA: BioMarin To Develop Former Repligen Drugs

Animal Studies Bode Well for MTM Gene Therapy

FA Drug RG2833 Moves from Repligen to BioMarin

ALS Care Checklist Developed

DMD: What's Next for Drisapersen?

Eteplirsen Data Still Strong: Treated Boys with DMD Stable at 120 Weeks

DMD: Prosensa to Present Webcasts on Drug Development

Dutch biopharmaceutical company Prosensa, developer of the experimental drug drisapersen and other experimental compounds for Duchenne muscular dystrophy (DMD), will update the investor community via a Thursday, Jan. 16, 2014, presentation at the J.P. Morgan Healthcare Conference in San Francisco. The presentation will be webcast at 10 a.m. Pacific time/1 p.m. Eastern time.

On Tuesday, Jan. 21, at 8 a.m. Eastern time, Prosensa will conduct a separate webinar for DMD patients and families.

Pages